

DAFTAR PUSTAKA

- Adrian, S.J., Tommy, 2019. Hipertensi Esensial: Diagnosis dan tatalaksana terbaru pada dewasa. Cdk-274 46, 172–178
- Albini, A., Di, G., Douglas, G., Noonan, M., Lombardo, M., 2020. The SARS - CoV - 2 receptors, ACE - 2 is expressed in many different cell types : implications for ACE - inhibitor - and angiotensin II receptor blocker - based cardiovascular therapies. Intern. Emerg. Med. 15, 759–766. <https://doi.org/10.1007/s11739-020-02364-6>
- Alrashed, A.A., Khan, T.M., Alhusseini, N.K., Asdaq, S.M.B., Enani, M., Alosaimi, B., Alkhani, N.M., Mohzari, Y., Alghalbi, M.M., Alfahad, W., Alanazi, M.A., Albujaidya, A.S., Ben-Akresh, A., Almutairi, M., Abraham, I., Alamer, A., 2021. The severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. J. Infect. Public Health 14, 726–733. <https://doi.org/10.1016/j.jiph.2021.03.004>
- An, J., Wei, R., Zhou, H., Luong, T.Q., Gould, M.K., Mefford, M.T., Harrison, T.N., Creekmur, B., Lee, M.S., Sim, J.J., Brettler, J.W., Martin, J.P., Ong-Su, A.L., Reynolds, K., 2021. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were used and covid-19 infection among 824 650 patients with hypertension from our integrated healthcare system. J. Am. Heart Assoc. 10, 1–7. <https://doi.org/10.1161/JAHA.120.019669>
- Arum, Y.T.G., 2019. Higeia Journal of Public Health. Higeia J. Public Heal. Res. Dev. 3, 84–94. <https://doi.org/10.15294>
- Bae, D.J., Tehrani, D.M., Rabadia, S. V., Frost, M., Parikh, R. V., Califon-Press, M., Aksoy, O., Umar, S., Ardehali, R., Rabbani, A., Bokhoor, P., Nair, A., Currier, J., Tobis, J., Fonarow, G.C., Dave, R., Rafique, A.M., 2020. Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19. Am. J. Cardiol. 132, 150–157. <https://doi.org/10.1016/j.amjcard.2020.07.007>
- Bean, D.M., Kraljevic, Z., Searle, T., Bendayan, R., Kevin, O., Pickles, A., Folarin, A., Roguski, L., Noor, K., Shek, A., Zakeri, R., Shah, A.M., Teo, J.T.H., Dobson, R.J.B., 2020. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur. J. Heart Fail. 22, 967–974. <https://doi.org/10.1002/ejhf.1924>
- Braude, P., Carter, B., Short, R., Vilches-Moraga, A., Verduri, A., Pearce, L., Price, A., Quinn, T.J., Steckman, M., Collins, J., Bruce, E., Einarsson, A., Rickard, F., Mitchell, E., Holloway, M., Hesford, J., Barlow-Pay, F., Clini, E., Myint, P.K., Moug, S., McCarthy, K., Hewitt, J., 2020. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. IJC Hear. Vasc. 31, 100660. <https://doi.org/10.1016/j.ijcha.2020.100660>
- Cetinkal, G., Kocas, B.B., Ser, O.S., Kilci, H., Yilzid, S.S., Ozcan, S.N., Verdi, Y., Altinay, M., Kilickesmez, K., 2020. The Association Between Chronic Use of Renin-Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension. Sili Etfal HHassan Tip Bul. / Med. Bull. Sisli Hosp. 54, 399–404. <https://doi.org/10.14744/semb.2020.15689>
- Chan, J.F.W., Kok, K.H., Zhou, Z., Chu, H., To, K.K.W., Yuan, S., Yuen, K.Y., 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221–236. <https://doi.org/10.1080/22221751.2020.1719902>
- Chisholm-Burns, M.A., Wells, B.G., Schwinghammer, T.L., Kolesar, J.M., Rotschafer, J.C., Dipiro, J.T., 2020. Pharmacotherapy Principles & Practice. The Mc. Graw Hill Company, USA. <https://doi.org/10.1036/0071448802>
- Covino, M., De Matteis, G., Burzo, M.L., Santoro, M., Fuorlo, M., Sabia, L., Sandroni, C., Gasbarrini, A., Franceschi, F., Gambassi, G., 2020. Angiotensin-converting enzyme inhibitors or angiotensin

- II receptor blockers and prognosis of hypertensive patients hospitalized with COVID-19. *Intern. Med. J.* 50, 1483–1491. <https://doi.org/10.1111/imj.15078>
- Cui, H., Wu, F., Fan, Z., Cheng, X., Cheng, J., Fan, M., 2020. The effects of renin-angiotensin system inhibitors (RASi) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial. *Med. Clínica* (English Ed. 155, 295–298. <https://doi.org/10.1016/j.medcle.2020.06.007>
- Dipiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., Ellingrod, V., 2020. *Pharmacotherapy A Pathophysiologic Approach*, Eleventh. ed, The Mc. Graw Hill Company. The Mc. Graw Hill Company, USA.
- Dublin, S., Walker, R.L., Floyd, J.S., Shortreed, S.M., Fuller, S., Albertson-Junkans, L., Harrington, L.B., Greenwood-Hickman, M.A., Green, B.B., Psaty, B.M., 2021. Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study. *Am.J. Hypertens.* 34, 339–347. <https://doi.org/10.1093/ajh/hpaa168>
- ElAbd, R., AlTarrah, D., AlYouha, S., Bastaki, H., Almazeedi, S., Al-Haddad, M., Jamal, M., AlSabah, S., 2021. Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease. *Front. Med.* 8, 1–7. <https://doi.org/10.3389/fmed.2021.600385>
- Felice, C., Nardin, C., Di Tanna, G.L., Grossi, U., Bernardi, E., Scaldaferrì, L., Romagnoli, M., Tonon, L., Cavasin, P., Novello, S., Scarpa, R., Farnia, A., De Menis, E., Rigoli, R., Cinetto, F., Pauletto, P., Agostini, C., Rattazzi, M., 2020. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. *Am. J. Hypertens.* 33, 944–948. <https://doi.org/10.1093/ajh/hpaa096>
- Fosbøl, E.L., Butt, J.H., Østergaard, L., Andersson, C., Selmer, C., Kragholm, K., Schou, M., Phelps, M., Gislason, G.H., Gerds, T.A., Torp-Pedersen, C., Køber, L., 2020. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with COVID-19 Diagnosis and Mortality. *JAMA - J. Am. Med. Assoc.* 324, 168–177. <https://doi.org/10.1001/jama.2020.11301>
- Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., Zhao, Y., Wang, H., Liu, Y., Yin, Z., Zhang, R., Wang, R., Yang, M., Hui, C., Wijns, W., Mcevoy, J.W., Soliman, O., Onuma, Y., Serruys, P.W., Tao, L., Li, F., 2020. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. *Eur. Heart J.* 41, 2058–2066. <https://doi.org/10.1093/eurheartj/ehaa433>
- Hajra, A., Bandyopadhyay, D., 2020. COVID-19 and ACEi/ARB: NOT ASSOCIATED? *Am. J. Hypertens.* 1–24. <https://doi.org/10.1093>
- Haroon, S., Subramanian, A., Cooper, J., Anand, A., Gokhale, K., Byrne, N., Dhalla, S., Acosta-Mena, D., Taverner, T., Okoth, K., Wang, J., Chandan, J.S., Sainsbury, C., Zemedikun, D.T., Thomas, G.N., Parekh, D., Marshall, T., Sapey, E., Adderley, N.J., Nirantharakumar, K., 2021. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care. *BMC Infect. Dis.* 21, 1–14. <https://doi.org/10.1186/s12879-021-05951-w>
- Hasanah, D.Y., Nauli, S.E., Prima Putri, V.K., Arifianto, H., Suryana, N.M., Suryani, L.D., Aditya, W., Probodewi, P., 2020. Gangguan Kardiovaskular pada infeksi COVID 19. *Indones. J. Cardiol.* 41, 59–68. <https://doi.org/10.30701/ijc.994>
- Hidayani, W.R., 2020. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review. *J. Untuk Masy. Sehat* 4, 120–134. <https://doi.org/10.52643/jukmas.v4i2.1015>
- Hippisley-Cox, J., Young, D., Coupland, C., Channon, K.M., Tan, P.S., Harrison, D.A., Rowan, K., Aveyard, P., Pavord, I.D., Watkinson, P.J., 2020. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people. *Heart* 106, 1503–1511. <https://doi.org/10.1136/heartjnl-2020-317393>

- Huang, Z., Cao, J., Yao, Y., Jin, X., Luo, Z., Xue, Y., Zhu, C., Song, Y., Wang, Y., Zou, Y., Qian, J., Yu, K., Gong, H., Ge, J., 2020. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann. Transl. Med.* 8, 430–430. <https://doi.org/10.21037/atm.2020.03.229>
- Kementrian Kesehatan RI, 2020. PEDOMAN PENCEGAHAN DAN PENGENDALIAN CORONAVIRUS DISEASE (COVID-19), Kementrian Kesehatan. Kemenkes RI, Jakarta.
- Khera, R., Clark, C., Lu, Y., Guo, Y., Ren, S., Truax, B., Spatz, E.S., Murugiah, K., Lin, Z., Omer, S.B., Vojta, D., Krumholz, H.M., 2021. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with covid-19. *J. Am. Heart Assoc.* 10. <https://doi.org/10.1161/JAHA.120.018086>
- Kim, J.H., Baek, Y.H., Lee, H., Choe, Y.J., Shin, H.J., Shin, J.Y., 2021. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: A nationwide study. *Epidemiol. Health* 43, 1–9. <https://doi.org/10.4178/EPIH.E2021004>
- Lafaurie, M., Martin-Blondel, G., Delobel, P., Charpentier, S., Sommet, A., Moulis, G., 2021. The outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. *Fundam. Clin. Pharmacol.* 35, 194–203. <https://doi.org/10.1111/fcp.12613>
- Lam, K.W., Chow, K.W., Vo, J., Hou, W., Li, H., Richman, P.S., Mallipattu, S.K., Skopicki, H.A., Singer, A.J., Duong, T.Q., 2020. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcomes. *J. Infect. Dis.* 222, 1256–1264. <https://doi.org/10.1093/infdis/jiaa447>
- Levani, Y., Prastya, A.D., Mawaddatunnadila, S., 2021. Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. *J. Kedokt. dan Kesehat.* 17, 44–57.
- Li, J., Wang, X., Chen, J., Zhang, H., Deng, A., 2020. Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol.* 5, 825–830. <https://doi.org/10.1001/jamacardio.2020.1624>
- Li, M., Wang, Y., Ndiwane, N., Orner, M.B., Palacios, N., Mittler, B., Berlowitz, D., Kazis, L.E., Xia, W., 2021. The association of COVID-19 occurrence and severity with the use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. *PLoS One* 16, 1–16. <https://doi.org/10.1371/journal.pone.0248652>
- Liu, X., Liu, Y., Chen, K., Yan, S., Bai, X., Li, J., Liu, D., 2020. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study. *J. Med. Virol.* 93, 854–862. <https://doi.org/10.1002/jmv.26315>
- López-Otero, D., López-Pais, J., Cacho-Antonio, C.E., Antúnez-Muiños, P.J., González-Ferrero, T., Pérez-Poza, M., Otero-García, Ó., Díaz-Fernández, B., Bastos-Fernández, M., Bouzas-Cruz, N., Sanmartín-Pena, X.C., Varela-Román, A., Portela-Romero, M., Valdés-Cuadrado, L., Pose-Reino, A., González-Juanatey, J.R., 2021. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. *CARDIOVID registry. Rev. Española Cardiol. (English Ed.)* 74, 175–182. <https://doi.org/10.1016/j.rec.2020.05.018>
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W.J., Wang, D., Xu, W., Holmes, E.C., Gao, G.F., Wu, G., Chen, W., Shi, W., Tan, W., 2020. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 395, 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)

- Manutung, N.A., 2019. Terapi Perilaku Kognitif pada Pasien Hipertensi. Wineka Media, Malang.
- Matsuzawa, Y., Ogawa, H., Kimura, K., Konishi, M., Kirigaya, J., Fukui, K., Tsukahara, K., Shimizu, H., Iwabuchi, K., Yamada, Y., Saka, K., Takeuchi, I., Hirano, T., Tamura, K., 2020. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. *Hypertens. Res.* 43, 1257–1266. <https://doi.org/10.1038/s41440-020-00535-8>
- Mehta, N., Kalra, A., Nowacki, A.S., Anjewierden, S., Han, Z., Bhat, P., Carmona-Rubio, A.E., Jacob, M., Procop, G.W., Harrington, S., Milinovich, A., Svensson, L.G., Jehi, L., Young, J.B., Chung, M.K., 2020. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 5, 1020–1026. <https://doi.org/10.1001/jamacardio.2020.1855>
- Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., Gao, H., Liu, L., Zhang, G., 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg. Microbes Infect.* 9, 757–760. <https://doi.org/10.1080/22221751.2020.1746200>
- Nurarif, A., Kusuma, H., 2015. Aplikasi Asuhan Keperawatan Berdasarkan Diagnosa Medis & NANDA NIC-NOC. MediaAction, Yogyakarta.
- Oussalah, A., Gleye, S., Clerc Urmes, I., Laugel, E., Callet, J., Barbé, F., Orlowski, S., Malaplate, C., Aimone-Gastin, I., Caillierez, B.M., Merten, M., Jeannesson, E., Kormann, R., Olivier, J.L., Rodriguez-Guéant, R.M., Namour, F., Bevilacqua, S., Losser, M.R., Levy, B., Kimmoun, A., Gibot, S., Thilly, N., Frimat, L., Schvoerer, E., Guéant, J.L., 2020. Long-term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with Severe COVID-19: Results from a Referral Center Cohort in the Northeast of France. *Clin. Infect. Dis.* 71, 2447–2456. <https://doi.org/10.1093/cid/ciaa677>
- Palazzuoli, A., Mancone, M., De Ferrari, G.M., Forleo, G., Secco, G.G., Ruocco, G.M., D'Ascenzo, F., Monticone, S., Paggi, A., Vicenzi, M., Palazzo, A.G., Landolina, M., Taravelli, E., Tavazzi, G., Blasi, F., Infusino, F., Fedele, F., De Rosa, F.G., Emmett, M., Schussler, J.M., Tecson, K.M., McCullough, P.A., 2020. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. *J. Am. Heart Assoc.* 9, e017364. <https://doi.org/10.1161/JAHA.120.017364>
- Parwanto, M., 2020. Virus Corona (2019-nCoV) penyebab COVID-19. *J. Biomedika dan Kesehat.* 3. <https://doi.org/10.1038/nsmb1123>
- Reynolds, H.R., Adhikari, S., Pulgarin, C., Troxel, A.B., Iturrate, E., Johnson, S.B., Hausvater, A., Newman, J.D., Berger, J.S., Bangalore, S., Katz, S.D., Fishman, G.I., Kunichoff, D., Chen, Y., Ogedegbe, G., Hochman, J.S., 2020. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. *N. Engl. J. Med.* 382, 2441–2448. <https://doi.org/10.1056/nejmoa2008975>
- Rossi, L., Malagoli, A., Biagi, A., Zanni, A., Sticozzi, C., Comastri, G., Pannone, L., Gandolfi, S., Vergara, P., Villani, G.Q., 2021. Renin-angiotensin system inhibitors and mortality in patients with COVID-19. *Infection* 49, 287–294. <https://doi.org/10.1007/s15010-020-01550-0>
- Savarese, G., Benson, L., Sundström, J., Lund, L.H., 2021. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. *Eur. J. Heart Fail.* 23, 476–485. <https://doi.org/10.1002/ehf.2060>
- Selçuk, M., Çınar, T., Keskin, M., Çiçek, V., Kılıç, Ş., Kenan, B., Doğan, S., Asal, S., Günay, N., Yıldırım, E., Keskin, Ü., Orhan, A.L., 2020. Is the use of ACEI/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? *Clin. Exp. Hypertens.* 42, 738–742. <https://doi.org/10.1080/10641963.2020.1783549>

- Semenzato, L., Botton, J., Drouin, J., Baricault, B., Vabre, C., Cuenot, F., Penso, L., Herlemont, P., Sbidian, E., Weill, A., Dray-Spira, R., Zureik, M., 2021. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. *Hypertension* 833–842. <https://doi.org/10.1161/HYPERTENSIONAHA.120.16314>
- Soleimani, A., Kazemian, S., Karbalai Saleh, S., Aminorroaya, A., Shajari, Z., Hadadi, A., Talebpour, M., Sadeghian, H., Payandemehr, P., Sotoodehnia, M., Bahreini, M., Najmeddin, F., Heidarzadeh, A., Zivari, E., Ashraf, H., 2020. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients with Hypertension and Confirmed or Clinically Suspected COVID-19. *Am.J. Hypertens.* 33, 1102–1111. <https://doi.org/10.1093/ajh/hpaa149>
- Suryantoro, S.D., Thaha, M., Hayati, M.R., Yusuf, M., Pikir, B.S., Susilo, H., 2021. Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study. *F1000Research* 10, 1–19. <https://doi.org/10.12688/f1000research.51785.2>
- Tian, C., Li, N., Bai, Y., Xiao, H., Li, S., Ge, Q.G., Shen, N., Ma, Q.B., 2021. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. *World J. Clin. Cases* 9, 47–60. <https://doi.org/10.12998/wjcc.v9.i1.47>
- Wang, W., Zhao, X., Wei, W., Fan, W., Gao, K., He, S., Zhuang, X., 2021. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients. *BMC Infect. Dis.* 21, 1–8. <https://doi.org/10.1186/s12879-021-05821-5>
- Xiang, D., Ren, X., Chen, Q., Yu, H., Li, X., Liu, D., 2021. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19. *Clin. Exp. Hypertens.* 43, 305–310. <https://doi.org/10.1080/10641963.2020.1867160>
- Xu, J., Huang, C., Fan, G., Liu, Z., Shang, L., Zhou, F., Wang, Yeming, Yu, J., Yang, L., Xie, K., Huang, Z., Huang, L., Gu, X., Li, H., Zhang, Y., Wang, Yimin, Hayden, F.G., Horby, P.W., Cao, B., Wang, C., 2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. *Front. Med.* 14, 601–612. <https://doi.org/10.1007/s11684-020-0800>
- Yang, G., Tan, Z., Zhou, L., Yang, M., Peng, L., Liu, J., Cai, J., Yang, R., Han, J., Huang, Y., He, S., 2020. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients with COVID-19 and Hypertension: A Single-Center Retrospective Study. *Hypertension* 76, 51–58. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15143>
- Yuliana, 2020. The controversy of angiotensin receptor blockers (ARBs) angiotensin-converting enzyme inhibitors (ACEIs) prescription for hypertension patients in coronavirus disease 2019 (COVID-19) pandemic 52, 67–76. <https://doi.org/10.19106>
- Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.J., Xie, J., Liu, Y.M., Zhao, Y.C., Huang, Xuewei, Lin, L., Xia, M., Chen, M.M., Cheng, X., Zhang, X., Guo, D., Peng, Y., Ji, Y.X., Chen, J., She, Z.G., Wang, Y., Xu, Q., Tan, R., Wang, H., Lin, J., Luo, P., Fu, S., Cai, H., Ye, P., Xiao, B., Mao, W., Liu, L., Yan, Y., Liu, M., Chen, M., Zhang, X.J., Wang, X., Touyz, R.M., Xia, J., Zhang, B.H., Huang, Xiaodong, Yuan, Y., Rohit, L., Liu, P.P., Li, H., 2020. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. *Circ. Res.* 126, 1671–1681. <https://doi.org/10.1161/CIRCRESAHA.120.317134>
- Zhang, Y., Sha, T., Wu, F., Hu, H., Chen, Z., Li, H., Han, J., Song, W., Huang, Q., Zeng, Z., 2021. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. *Int. Heart J.* 62, 337–343. <https://doi.org/10.1536/ihj.20-323>
- Zhong, Y., Zhao, L., Wu, G., Hu, C., Wu, Chenfang, Xu, M., Dong, H., Zhang, Q., Wang, G., Yu, B., Lv, J., Wu, Chao, Zhang, S., Cao, C., Shu, L., Pan, Y., Liu, X., Wu, F., 2020. Impact of renin-

angiotensin system inhibitors uses on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. *J. Int. Med. Res.* 48. <https://doi.org/10.1177/0300060520979151>

Zhou, X., Zhu, J., Xu, T., 2020. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. *Clin. Exp. Hypertens.* 42, 656–660. <https://doi.org/10.1080/10641963.2020.1764018>